The role of radiolabeled anti-TNFα monoclonal antibodies for diagnostic purposes and therapy evaluation

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 6, 2010, Pages 639-653

  Glaudemans, A W J M ^a   Dierckx, R A J O ^a,b   Kallenberg, C G M ^a   Anzola Fuentes, K L ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

^c Clinica Colsanitas   (Colombia)

Author keywords

Diagnosis; Radiopharmaceuticals; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ADALIMUMAB TC 99M; CERTOLIZUMAB PEGOL; CHIMERIC ANTIBODY; ETANERCEPT; FLUORODEOXYGLUCOSE F 18; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; HUMAN IMMUNOGLOBULIN TC 99M; INFLIXIMAB; INFLIXIMAB TC 99M; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ANKYLOSING SPONDYLITIS; ANTIBODY LABELING; ANTIBODY RESPONSE; BEHCET DISEASE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COLITIS; COMPLEX REGIONAL PAIN SYNDROME; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; DRUG RECEPTOR BINDING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSCINTIGRAPHY; IMMUNOSTIMULATION; ISOTOPE LABELING; JOINT SCINTISCANNING; JUVENILE IDIOPATHIC ARTHRITSI; JUVENILE RHEUMATOID ARTHRITIS; LUNG SARCOIDOSIS; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN FUNCTION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECEPTOR BLOCKING; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ANIMAL; IMMUNOLOGY; INFLAMMATION; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATION; ISOTOPE LABELING; MOLECULAR IMAGING; PROGNOSIS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953108502     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21.
2. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
3. Abbas AK. Cytokines in cellular and molecular immunology. Elsevier Saunders 2009;267.
4. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
5. Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A. Molecular imaging of rheumatoid arthritis by radiolabeled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 2010;37:386-98.
6. Remicade (infliximab) package insert. Malvern, Pennsylvania: Centocor, Inc. Revised April 2007.
7. Scallon BJ, Moore MA, Trinh H, Knight DM ,Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
8. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
9. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85. (Pubitemid 36666774)
10. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
11. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61 Suppl 2:ii51-ii53.
12. Malviya G, Signore A, Lagana B, Dierckx RA. Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr Pharm Des 2008;14:2401-14.
13. Paul S, Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34(Suppl): 19-22.
14. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9:767-74.
15. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38. (Pubitemid 47080387)
16. Bradley JRTNF-mediated inflammatory disease. J Pathol 2008;214:149-60.
17. de Bois MH, Pauwels EK, Breedveld FC. New agents for scintigraphy in rheumatoid arthritis. Eur J Nucl Med 1995;22:1339-46.
18. Chianelli M, D'Alessandria C, Conti F, Priori R, Valesini G, Annovazzi A et al. New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nucl Med Mol Imaging 2006;50:217-25. (Pubitemid 44649661)
19. Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992;35:1170-8.
20. Williams RO. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol 2007;361:265-84. (Pubitemid 350183212)
21. Appel H, Loddenkemper C, Miossec P. Rheumatoid arthritis and ankylosing spondylitis - pathology of acute inflammation. Clin Exp Rheumatol 2009;27:S15-S19.
22. Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010;29:763-70.
23. Braun J, Kalden JR. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S164-S167.
24. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
25. Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 2000;5:507-11.
26. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7. (Pubitemid 35222210)
27. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-91. (Pubitemid 351988090)
28. Glaudemans AW, Maccioni F, Mansi L, Dierckx RA, Signore A. Imaging of cell trafficking in Crohn's disease. J Cell Physiol 2010;223:562-71.
29. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
30. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-98. (Pubitemid 29165293)
31. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8. (Pubitemid 29013489)
32. Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Seris M, Vassalli P. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol 1998;28:730-44. (Pubitemid 28101750)
33. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
34. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
35. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
36. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993;94:354-62. (Pubitemid 23337840)
37. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15.
38. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829-35.
39. Antoniu SATargeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010;14:21-9.
40. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008;31:1189-96.
41. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W, Jr. et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:201-8.
42. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007;26:1969-71.
43. Annovazzi A, D'Alessandria C, Caprili R, Viscido A, Corsetti F, Parisella MG. Radiolabelling of a monoclonal anti-TNF-alpha antibody with 99mTc: in vitro studies. Q J Nucl Med 2002;46:27.
44. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G et al. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005;52:1224-6. (Pubitemid 40530130)
45. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G et al. Imaging and serum analysis of immune complex formation of radiolabeled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6. (Pubitemid 46226064)
46. Tsopelas C, Penglis S, Ruskiewicz A, Bartholomeusz DL. Scintigraphic imaging of experimental colitis with technetium-99m-infliximab in the rat. Hell J Nucl Med 2006;9:85-9. (Pubitemid 44209739)
47. D'Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A et al. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies. Q J Nucl Med Mol Imaging 2007;51:334-42. (Pubitemid 350267704)
48. de Mos M, Huygen FJ, Hoeven-Borgman M, Dieleman JP, Ch Stricker BH, Sturkenboom MC. Outcome of the complex regional pain syndrome. Clin J Pain 2009;25:590-7.
49. Dommerholt J. Complex regional pain synrome. Part 1: History, diagnostic criteria and etiology. J Bodywork Mov Ther 2004;8:167-77. (Pubitemid 38858061)
50. Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-alpha? Neurology 2005;65:311-3.
51. Schinkel C, Scherens A, Koller M, Roellecke G, Muhr G, Maier C. Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I) - longitudinal investigations and differences to control groups. Eur J Med Res 2009;14:130-5.
52. Bernateck M, Karst M, Gratz KF, Meyer GJ, Fischer MJ, Knapp WH et al. The first scintigraphic detection of tumor necrosis factor-alpha in patients with complex regional pain syndrome type 1. Anesth Analg 2010;110:211-5.
53. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-8.
54. 99mTechnetium labelled anti-TNF-α antibodies for the therapy-decision making and follow-up of patients with rheumatoid arthritis. Q J Nucl Med Mol Imaging 2008;52(Suppl 1(2): 13-4.
55. Barrera P, Oyen WJ, Boerman OC, van Riel PL. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:825-8. (Pubitemid 37026491)
56. Malviya G, de Vries EFJ, Dierckx RAJO, Signore A. Radiopharmaceuticals for imaging chronic lymphocytic inflammation. Bra Arch Bio Tech 2010;50:1-13.
57. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:143-9.
58. Tu Z, Chu W, Zhang J, Dence CS, Welch MJ, Mach RH. Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis. Nucl Med Biol 2005;32:437-43.
59. Jagtap PG, Degterev A, Choi S, Keys H, Yuan J, Cuny GD. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem 2007;50:1886-95. (Pubitemid 46626598)
60. Gao M, Lola CM, Wang M, Miller KD, Sledge GW, Hutchins GD et al. Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha). Appl Radiat Isot 2010;68:1950-8.